MYD88L265P及CXCR4WHIM基因突变在华氏巨球蛋白血症中的意义

摘要

Waldenstrom macroglobulinemia (WM) is a lymphoplasmacytic lymphoma characterized by serum monoclonal IgM immunoglobulin.Recently,the high mutation rates of MYD88L265P and CXCR4WHIM have been documented in WM.Furthermore,MYD88L265P and CXCR4WHIM are related to the response to target drugs.This article reviews the significances of MYD88L265P and CXCR4WHIM in the diagnosis and treatment of WM.%华氏巨球蛋白血症是一种以分泌单克隆免疫球蛋白M为特征的淋巴浆细胞淋巴瘤.MYD88 L265P和CXCR4WHIM两种体细胞突变在华氏巨球蛋白血症患者中存在较高的突变率,且突变情况与靶向药物的疗效相关.本文主要综述MYD88L265P及CXCR4WHIM基因突变在华氏巨球蛋白血症诊断和治疗中的意义.